VivoSim Labs (VIVS) Asset Writedowns and Impairment (2019 - 2024)
VivoSim Labs (VIVS) posted Asset Writedowns and Impairment of $600000.0 for Q4 2024, up 200.0% on a QoQ basis from $200000.0 in Q3 2019.
Powered by 
Analysis
VivoSim Labs (VIVS) Asset Writedowns and Impairment (2019 - 2024) Analysis & Trends
VivoSim Labs has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $600000.0 in Q4 2024.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $600000.0 in Q4 2024; TTM through Mar 2026 was $600000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $798000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment was $600000.0 for Q4 2024 at VivoSim Labs, up from $200000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $600000.0 in Q4 2024, with the low at $600000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |